# Viramune XR - (400 mg; Tablet, Extended Release)

| | | | |
|---|---|---|---|
| **Generic Name** | Nevirapine | **Innovator** | Boehringer Ingelheim |
| **Dosage** | 400 mg; Tablet, Extended Release | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | None | **Tentative Approvals** | Less Than 5 |
| **Final Approvals** | More Than 5 | **Generic Launches** | None |
| **Indication** | Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 6 to less than 18 years of age | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.